Last reviewed · How we verify
SOF+DCV
At a glance
| Generic name | SOF+DCV |
|---|---|
| Also known as | GS-7977, PSI-7977, Sovaldi®, BMS-790052, Daklinza® |
| Sponsor | Humanity and Health Research Centre |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
- A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection (PHASE4)
- Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus (PHASE2,PHASE3)
- Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera (EARLY_PHASE1)
- Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- COVID-19 Prophylaxis South Africa (COVER HCW) (PHASE2)
- Re-treatment of HCV Following DAA Failure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOF+DCV CI brief — competitive landscape report
- SOF+DCV updates RSS · CI watch RSS
- Humanity and Health Research Centre portfolio CI